TD Cowen analyst Ritu Baral initiates coverage on Sionna Therapeutics (NASDAQ: SION) with a Buy rating.The analyst comments "SION's pipeline ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE